HK Stock Market Move | VISEN PHARMA-B (02561) rises by over 12% again, Longyou growth hormone is about to be approved. The company recently reached a strategic cooperation agreement with Tofflon Science and Technology Group.

VISEN PHARMA-B(02561) rose by more than 12%, as of the report, it increased by 7.11% to 35.26 Hong Kong dollars, with a turnover of 1.9082 million Hong Kong dollars. On the news front, Anhui Anke Biotechnology recently disclosed progress in cooperation, and the long-term growth hormone cooperation with Visen Pharma is about to be approved. It is reported that on July 14th, Anhui Anke Biotechnology announced that the company had signed a strategic cooperation framework agreement with Visen Pharma to jointly promote the popularization of long-action growth hormone in the Chinese market. It is worth noting that on November 6th, during the eighth China International Import Expo, Visen Pharma reached a strategic cooperation on dual-chamber lyophilized preparation technology with Tofflon Science and Technology Group, a leading domestic pharmaceutical equipment manufacturer, and signed an industrial synergy agreement with Lingang New Area Management Committee and Lingang Group Trade and Business Platform, marking the further implementation of its "global innovation, China accelerate" strategy.